enzastaurin has been researched along with Benign Neoplasms in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 13 (61.90) | 29.6817 |
| 2010's | 8 (38.10) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bourhill, T; Johnston, RN; Narendran, A | 1 |
| Grigat, J; Keppner-Witter, S; Lange, L; Spänkuch, B | 1 |
| Baldwin, J; Bell, RL; Coutant, DE; Hall, SD; Kulanthaivel, P; Pitou, C; Turner, PK; Wijayawardana, SR | 1 |
| Darstein, CL; Lesimple, T; Musib, L; Ng, WT; Welch, PA | 1 |
| Cai, R; Cui, Y; Fang, X; Fu, X; Hong, H; Huang, H; Li, S; Li, X; Lin, T; Lin, X; Yang, N; Zhang, W | 1 |
| Giaccone, G; Graefe, T; Hanauske, AR; Kuenen, B; Lahn, M; McNealy, P; Musib, LC; Thornton, D; Weigang-Köhler, K; Yilmaz, E | 1 |
| Chen, XG; Li, XY | 1 |
| Koshiji, M; Minami, H; Mukohara, T; Nagai, S; Yoshizawa, K | 1 |
| Chhatwani, L; Colevas, AD; Decker, R; Fisher, GA; Krupitskaya, Y; Latz, JE; Padda, SK; San Pedro-Salcedo, M; Wakelee, HA | 1 |
| Armstrong, DK; Carducci, MA; Collins, C; Day, J; Decker, R; Ermisch, S; Kornberg, L; Nicol, S; Nwankwo, N; Resta, L; Thornton, D; Wang, T; Zhang, Z | 1 |
| Alice Miller, M; Pearce, HL | 1 |
| Teicher, BA | 1 |
| Basche, M; Britten, CD; Carducci, M; Cook, CA; Eckhardt, SG; Green, LJ; Herbst, RS; Jaken, S; Marder, P; Musib, LC; Ray, C; Thornton, D | 1 |
| Brahmer, JR; Carducci, MA; Cole, P; Enas, N; Herbst, RS; Kies, MS; Musib, L; Pili, R; Riddle, J; Schmidt, J; Sinha, V; Sullivan, R; Thornton, DE; Truong, M | 1 |
| Eismann, U; Hanauske, AR; Hanauske-Abel, H; Lahn, MM; Oberschmidt, O | 1 |
| Beerepoot, LV; Beijnen, JH; Enas, N; Mehra, N; Musib, L; Radema, SA; Rademaker-Lakhai, JM; Schellens, JH; van Hal, G; van Maanen, R; Vermaat, JS; Visseren-Grul, CM; Voest, EE; Witteveen, EO | 1 |
| Ma, S; Rosen, ST | 1 |
| Blatter, J; Chen, V; Eismann, U; Hanauske, AR; Hanauske-Abel, HM; Lahn, M; Ma, D; Oberschmidt, O; Pospisil, H | 1 |
| Baldwin, J; Basche, M; Britten, CD; Camidge, DR; Darstein, C; Finn, RS; Gail Eckhardt, S; Gore, L; Holden, SN; Leong, S; Musib, L; O'Bryant, CL; Thornton, D | 1 |
| Fields, AP; Murray, NR | 1 |
| Chen, YB; LaCasce, AS | 1 |
5 review(s) available for enzastaurin and Benign Neoplasms
| Article | Year |
|---|---|
Enzastaurin: A lesson in drug development.
Topics: Animals; Antineoplastic Agents; Drug Design; Humans; Indoles; Neoplasms; Protein Kinase C beta | 2017 |
Understanding Disease-Drug Interactions in Cancer Patients: Implications for Dosing Within the Therapeutic Window.
Topics: Acute-Phase Proteins; Cytochrome P-450 Enzyme System; Cytokines; Drug Interactions; Humans; Imidazoles; Indoles; Inflammation; Meta-Analysis as Topic; Midazolam; Neoplasms; p38 Mitogen-Activated Protein Kinases; Protein Kinase C beta; Pyridines | 2015 |
[Role of PKCbeta in the malignant tumors and enzastaurin, a PKCbeta inhibitor].
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Clinical Trials as Topic; Humans; Indoles; Neoplasms; Protein Kinase C; Protein Kinase C beta; Protein Kinase Inhibitors | 2009 |
Enzastaurin.
Topics: Administration, Oral; Antineoplastic Agents; Clinical Trials as Topic; Disease Progression; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Indoles; Neoplasms; Protein Kinase C; Protein Kinase C beta; Treatment Outcome | 2007 |
Enzastaurin.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Clinical Trials as Topic; Enzyme Activation; Humans; Indoles; Neoplasm Invasiveness; Neoplasm Proteins; Neoplasms; Neovascularization, Pathologic; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase C; Protein Kinase C beta; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Salvage Therapy; Signal Transduction; Vascular Endothelial Growth Factor A | 2008 |
9 trial(s) available for enzastaurin and Benign Neoplasms
| Article | Year |
|---|---|
Effects of enzastaurin and its metabolites on the QT interval in cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Electrocardiography; Female; Heart Rate; Humans; Indoles; Long QT Syndrome; Male; Middle Aged; Neoplasms | 2016 |
A pharmacokinetic and safety study of a fixed oral dose of enzastaurin HCl in native Chinese patients with refractory solid tumors and lymphoma.
Topics: Adult; Aged; Asian People; Female; Humans; Indoles; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasms | 2016 |
Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in combination with pemetrexed in advanced/metastatic cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Glutamates; Guanine; Humans; Indoles; Male; Middle Aged; Neoplasms; Pemetrexed | 2009 |
Phase I dose escalation and pharmacokinetic study of oral enzastaurin (LY317615) in advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Electrocardiography; Female; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Protein Kinase Inhibitors | 2010 |
A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Interactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Indoles; Male; Middle Aged; Neoplasms; Quinazolines | 2012 |
Phase I study of enzastaurin and bevacizumab in patients with advanced cancer: safety, efficacy and pharmacokinetics.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Female; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Indoles; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Treatment Outcome; Young Adult | 2013 |
Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Flow Cytometry; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Indoles; Male; Middle Aged; Neoplasms; Protein Kinase C; Protein Kinase C beta; Protein Kinase Inhibitors | 2006 |
Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase C beta-inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced cancer.
Topics: AC133 Antigen; Adult; Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; CD146 Antigen; Cisplatin; Deoxycytidine; Endothelium, Vascular; Female; Gemcitabine; Glycoproteins; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms; Peptides; Prognosis; Protein Kinase C; Protein Kinase C beta; RNA, Messenger; Survival Rate | 2007 |
A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Female; Floxuridine; Fluorouracil; Follow-Up Studies; Humans; Indoles; Male; Middle Aged; Monocytes; Neoplasms; Phosphorylation; Protein Kinase C; Protein Kinase C beta | 2008 |
7 other study(ies) available for enzastaurin and Benign Neoplasms
| Article | Year |
|---|---|
Combinatorial inhibition of Plk1 and PKCβ in cancer cells with different p53 status.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzylamines; Blotting, Western; Cell Cycle Proteins; Cell Proliferation; Flow Cytometry; HCT116 Cells; HeLa Cells; Humans; Indoles; MCF-7 Cells; Neoplasms; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pyridines; Tumor Suppressor Protein p53 | 2014 |
The evolution of cancer research and drug discovery at Lilly Research Laboratories.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Deoxycytidine; Drug Industry; Gemcitabine; Glutamates; Guanine; History, 20th Century; Humans; Indoles; Neoplasms; Pemetrexed; United States | 2005 |
Hypoxia, tumor endothelium, and targets for therapy.
Topics: Animals; Cell Line, Tumor; Endothelium, Vascular; Gene Expression; Humans; Hypoxia; Indoles; Mice; Models, Biological; Neoplasm Transplantation; Neoplasms; Neovascularization, Pathologic; Transplantation, Heterologous; Vascular Endothelial Growth Factor A | 2005 |
Development and validation of a drug activity biomarker that shows target inhibition in cancer patients receiving enzastaurin, a novel protein kinase C-beta inhibitor.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Capecitabine; Cell Line, Tumor; Clinical Trials, Phase I as Topic; Deoxycytidine; Enzyme Activators; Enzyme Inhibitors; Flow Cytometry; Fluorouracil; Follow-Up Studies; Humans; Indoles; Leukocytes, Mononuclear; Monocytes; Neoplasms; Protein Kinase C; Protein Kinase C beta; Reproducibility of Results; Sensitivity and Specificity; Signal Transduction; Structure-Activity Relationship; Treatment Outcome | 2006 |
Antitumor activity of enzastaurin (LY317615.HCl) against human cancer cell lines and freshly explanted tumors investigated in in-vitro [corrected] soft-agar cloning experiments.
Topics: Agar; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Culture Media; Dose-Response Relationship, Drug; Humans; Indoles; Neoplasms; Neoplastic Stem Cells; Protein Kinase C; Protein Kinase C beta; Protein Kinase Inhibitors; Time Factors; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2007 |
Correlations of mRNA expression and in vitro chemosensitivity to enzastaurin in freshly explanted human tumor cells.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Gene Expression; Glycogen Synthase Kinase 3; Humans; Indoles; Interleukin-8; Neoplasms; RNA, Messenger; Tumor Cells, Cultured | 2008 |
Protein kinase C isozymes as therapeutic targets for treatment of human cancers.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Humans; Indoles; Isoenzymes; K562 Cells; Lung Neoplasms; Mice; Neoplasms; Oncogenes; Protein Kinase C; Rats; Signal Transduction | 2008 |